ABILITY Neurotech, a clinical-stage brain-computer interface (BCI) company developing a neural data platform to restore communication, movement and independence for individuals with severe ...
MedPage Today on MSN
Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer
Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival ...
Targeting KMA seeks to spare normal immunoglobulin-producing plasma cells, differentiating from BCMA-directed CAR T ...
Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are ...
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...
Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma June 2, 2026 8:00 ...
“The results support daraxonrasib as the new standard of care for patients with previously treated metastatic PDAC,” said Brian Wolpin, MD. Daraxonrasib reduced the risk of death by 60% compared with ...
Researchers affiliated with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) are set to unveil new findings from a diverse portfolio of clinical trials and translational research at the American ...
Discusses Clinical Data and Updated Development Strategy for Darlifarnib June 3, 2026 3:15 PM EDTCompany ParticipantsTroy ...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...
A Brazilian study published in the journal Ecography indicates that the biodiversity of anuran amphibians (toads and frogs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results